Postes actifs de Alex Qiao
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Ablaze Pharmaceuticals
 Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Ablaze Pharmaceuticals is a Chinese clinical-stage pharmaceutical company founded in 2021 with a mission to bring advanced targeted radiopharmaceutical therapies to benefit cancer patients. Ablaze Pharma has secured a partnership with Rayzebio, Inc., an innovative radiopharmaceutical company based in CA, to gain exclusive development and commercial rights to a series of Rayzebio's products in the greater region. The company is based in Jing'an District, China. The company leverages its team's extensive business experience and network in cross-border product development and deal making to become the leader and partner of choice in the emerging TRT market. Alex Qiao has been the CEO of the company since 2021. | Directeur/Membre du Conseil | 01/04/2021 | - |
| Directeur Général | 01/04/2021 | - | |
| President | 01/04/2021 | - |
Historique de carrière de Alex Qiao
Statistiques
Internationale
| Chine | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| President | 1 |
Sectorielle
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Ablaze Pharmaceuticals is a Chinese clinical-stage pharmaceutical company founded in 2021 with a mission to bring advanced targeted radiopharmaceutical therapies to benefit cancer patients. Ablaze Pharma has secured a partnership with Rayzebio, Inc., an innovative radiopharmaceutical company based in CA, to gain exclusive development and commercial rights to a series of Rayzebio's products in the greater region. The company is based in Jing'an District, China. The company leverages its team's extensive business experience and network in cross-border product development and deal making to become the leader and partner of choice in the emerging TRT market. Alex Qiao has been the CEO of the company since 2021. | Health Technology |
